Page 4 - Timothys Ernst News Today

Fisher Asset Management LLC lessened its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 2.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 144,522 shares of the medical research company’s stock after selling 3,597 shares during the quarter. Fisher […]

Tobam cut its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 26.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 72 shares of the medical research company’s stock after selling 26 shares during the period. Tobam’s […]

Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) have received an average recommendation of “Buy” from the six ratings firms that are presently covering the company, MarketBeat Ratings reports. Five investment analysts have rated the stock with a buy recommendation. The average 1 year price objective among analysts that have updated their coverage on […]

Cohen Capital Management Inc. cut its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 10.2% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 660 shares of the medical research company’s stock after selling 75 shares during the quarter. Cohen […]

Bank of Montreal Can lifted its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 189.0% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 69,058 shares of the medical research company’s stock after acquiring an additional 45,162 shares […]

Should You Buy or Sell Bio-Rad Laboratories Stock? Get The Latest BIO Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.